Answers are grounded in this paper and cite their sources.
X-linked myotubular myopathy (XLMTM) is a rare pediatric neuromuscular disease caused by loss-of-function variants in myotubularin (MTM1 ). With novel therapies entering clinical trials, the discovery of robust biomarkers that reflect disease severity and therapeutic efficacy is critically required. Using high-throughput and directed approaches, we identified a decrease in miR-133a expression as a marker of XLMTM disease in skeletal muscle and plasma of a mouse model of XLMTM ( Mtm1 KO). miR-133a is a muscle-enriched non-coding RNA (myomiR) involved in muscle development and function and is implicated in the regulation of the XLMTM modifier gene DNM2 . miR-133a has emerged as both a treatment-effect biomarker and therapeutic candidate in other neuromuscular diseases. We demonstrate that miR-133a expression negatively correlates with disease severity in Mtm1 KO mice and is upregulated in response to treatments that improve DNM2 expression and/or significantly rescue XLMTM. Moreover, we show that miR-133a expression in treated Mtm1 KO mice positively correlates with treatment response and was shown to have high discrimination accuracy for XLMTM by linear discriminant analysis (79%–90%) and receiver operating characteristic curve analysis (AUC >0.80). These results support miR-133a as a robust, circulating biomarker that reflects disease severity and treatment response in XLMTM.
No takes yet. Share an insight, caveat, or question.
Maani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: